The U.S. Food and Drug Administration has taken a landmark step toward modernizing the safety oversight of beauty products with the launch of its new AI-powered Adverse Event Monitoring System (AEMS). This unified platform, announced in March 2026, consolidates decades of fragmented data into a single, real-time dashboard capable of processing millions of adverse event reports annually—including those related to cosmetics, drugs, and medical devices. For consumers, salon professionals, and manufacturers, the shift promises greater transparency and faster identification of potential safety risks, from skin irritation to more serious reactions.
Until recently, tracking complaints about beauty products was a cumbersome process. The FDA’s legacy systems—scattered across seven separate databases—were not only inefficient but also failed to provide the public with timely access to critical safety information. With AEMS, the agency has replaced these outdated platforms with a single, intuitive interface that allows users to search, filter, and download adverse event reports in real time. The new system is designed to flag emerging patterns, such as clusters of irritation, burns, discoloration, or other adverse reactions, enabling quicker responses from regulators and manufacturers.
“The FDA’s previous adverse event reporting systems were outdated and fragmented, making important data difficult to access,” said FDA Commissioner Marty Makary, M.D., M.P.H. “We’re fixing the problem through a major modernization initiative. Starting today, the FDA will have a single, intuitive adverse event platform that will better serve agency scientists, researchers, and the public.” The agency expects the transition to AEMS to save approximately $120 million over the next five years while significantly improving the efficiency and accuracy of postmarket surveillance.
How the New System Works
The FDA Adverse Event Monitoring System (AEMS) integrates data from multiple sources, including voluntary reports from healthcare professionals, consumers, salon professionals, and cosmetologists, as well as mandatory submissions required by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This comprehensive approach ensures that adverse events related to cosmetic products—such as moisturizers, shampoos, conditioners, hair dyes, and tattoos—are captured and analyzed in real time.
Users can now search the AEMS dashboard by product name, adverse event type, severity level, date, or report source. For example, a consumer concerned about reports of hair loss or scalp irritation linked to a specific hair dye can quickly access the latest data. The dashboard also allows users to download report listings or datasets, with updates occurring daily. It is important to note, however, that the reports have not been verified by the FDA, and their publication does not indicate a definitive causal relationship between the product and the adverse event.
Key Features of AEMS
- Real-time updates: Adverse event reports are published daily, ensuring the public has access to the most current information.
- Comprehensive searchability: Users can filter reports by product type, adverse event, severity, and date.
- Transparency: The system consolidates data from multiple legacy databases, including FAERS (FDA Adverse Event Reporting System) and VAERS (Vaccine Adverse Event Reporting System).
- Cost savings: The transition to AEMS is expected to save the agency millions of dollars annually by streamlining operations and reducing the need for manual data processing.
Who Benefits from AEMS?
The launch of AEMS is a game-changer for several key stakeholders:
Consumers
For the average consumer, AEMS provides unprecedented access to safety data. Whether researching a new skincare product, hair dye, or makeup brand, users can now quickly assess whether others have reported adverse reactions. This level of transparency empowers consumers to make more informed choices about the products they use daily.
Salon and Spa Professionals
Salon professionals, cosmetologists, and estheticians are on the front lines of beauty product use and can benefit from AEMS by staying informed about emerging safety concerns. For example, if multiple clients report irritation from a new hair treatment, a stylist can check the dashboard to see if others have experienced similar issues, prompting them to advise clients accordingly or discontinue use of the product.
Manufacturers
Beauty brands can use AEMS to monitor their products’ safety profiles in real time. By identifying and addressing potential issues quickly, manufacturers can mitigate risks, recall products if necessary, and maintain consumer trust. The system also allows companies to proactively communicate with regulators and the public about any safety concerns.
Regulators and Researchers
The FDA and other researchers will benefit from the enhanced data quality and accessibility provided by AEMS. The system’s AI capabilities are designed to detect patterns and potential safety signals more efficiently, enabling regulators to take timely action when necessary. This modernization aligns with the agency’s broader goal of providing “radical transparency” into the safety of regulated products.
What’s Next for AEMS?
By the end of May 2026, AEMS will contain real-time adverse event reports for all FDA-regulated products, including medical devices and human foods. The agency plans to continue enhancing the platform with new features, such as improved application program interfaces (APIs) and advanced data analytics tools. These upgrades will further empower users to explore safety data and contribute to ongoing discussions about product safety.
The FDA has also emphasized that AEMS is part of a broader initiative to modernize its postmarket surveillance capabilities. As the system evolves, it is expected to play a crucial role in identifying and mitigating risks across a wide range of consumer products.
How to Report an Adverse Event
Consumers and professionals who experience adverse reactions to cosmetic products are encouraged to report them through the FDA’s MedWatch program. Reporting helps the agency identify potential safety issues and take appropriate action. The new AEMS dashboard will make it easier than ever to track the status of reported events and see if others have experienced similar problems.
For more information, visit the FDA’s MedWatch reporting page or explore the FAERS Public Dashboard for Cosmetic Products.
Why This Matters
The beauty industry is a multi-billion-dollar sector with millions of products on the market, each with the potential to cause harm if not properly regulated. The launch of AEMS marks a significant step forward in ensuring that consumers, professionals, and manufacturers have the tools they need to prioritize safety. By consolidating data, improving transparency, and leveraging AI, the FDA is setting a new standard for how adverse event reporting is managed and communicated.
As the system continues to evolve, it will be critical for all stakeholders to engage with the data responsibly. While AEMS provides valuable insights, it is essential to remember that reported adverse events are not always indicative of a product’s overall safety profile. The FDA continues to emphasize that AEMS is a tool for identifying potential signals, not a definitive indicator of cause and effect.
For those interested in staying updated on AEMS and other FDA initiatives, the agency encourages visiting the official AEMS page and subscribing to FDA newsletters for the latest announcements.
As AEMS rolls out fully and historical data is migrated to the new platform, the beauty industry can look forward to a future where safety is not just a priority but a collaborative effort between regulators, manufacturers, and consumers.
Have you used the new AEMS dashboard to research a product? Share your experience or questions in the comments below. For more updates, follow TIME News for the latest in health, science, and regulatory news.
